Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Denis, Kandolo"'
Autor:
Berthe Miwanda, Sandra Moore, Jean-Jacques Muyembe, Georges Nguefack-Tsague, Ickel Kakongo Kabangwa, Daniel Yassa Ndjakani, Ankur Mutreja, Nicholas R. Thomson, Helene Thefenne, Eric Garnotel, Gaston Tshapenda, Denis Kandolo Kakongo, Guy Kalambayi, Renaud Piarroux
Publikováno v:
Emerging Infectious Diseases, Vol 21, Iss 5, Pp 847-851 (2015)
We analyzed 1,093 Vibrio cholerae isolates from the Democratic Republic of the Congo during 1997–2012 and found increasing antimicrobial drug resistance over time. Our study also demonstrated that the 2011–2012 epidemic was caused by an El Tor va
Externí odkaz:
https://doaj.org/article/a6374169944044059606e6323303698e
Autor:
Dominique A Caugant, Paul A Kristiansen, Xin Wang, Leonard W Mayer, Muhamed-Kheir Taha, Rasmata Ouédraogo, Denis Kandolo, Flabou Bougoudogo, Samba Sow, Laurence Bonte
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e46019 (2012)
BACKGROUND: The serogroup A conjugate meningococcal vaccine, MenAfriVac, was introduced in mass vaccination campaigns in December 2010 in Burkina Faso, Mali and Niger. In the coming years, vaccination will be extended to other African countries at ri
Externí odkaz:
https://doaj.org/article/f486139256f4424bb540a6fb2564626c
Autor:
Hélène Thefenne, Guy Kalambayi, Gaston Tshapenda, Sandra Moore, Daniel Yassa Ndjakani, Renaud Piarroux, Eric Garnotel, Berthe Miwanda, Denis Kandolo Kakongo, Jean-Jacques Muyembe, Nicholas R. Thomson, Ankur Mutreja, Georges Nguefack-Tsague, Ickel Kakongo Kabangwa
Publikováno v:
Emerging Infectious Diseases, Vol 21, Iss 5, Pp 847-851 (2015)
Emerging Infectious Diseases
Emerging Infectious Diseases
We analyzed 1,093 Vibrio cholerae isolates from the Democratic Republic of the Congo during 1997-2012 and found increasing antimicrobial drug resistance over time. Our study also demonstrated that the 2011-2012 epidemic was caused by an El Tor varian
Autor:
Jennifer Dolan Thomas, Paul A. Kristiansen, Denis Kandolo, Marie-Pierre Préziosi, F. Marc LaForce, Abdoul-Salam Ouédraogo, Rasmata Ouédraogo, Thomas A. Clark, Absatou Ky Ba, Dominique A. Caugant, Idrissa Sanou, Fabien Diomandé, Lassana Sangaré
Publikováno v:
Journal of Clinical Microbiology. 50:4020-4027
Neisseria lactamica is a true commensal bacterium occupying the same ecological niche as the pathogenic Neisseria meningitidis , which is responsible for outbreaks and large epidemics, especially in sub-Saharan Africa. To better understand the epidem
Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity
Autor:
Absatou Ky Ba, Marie-Pierre Préziosi, Stacey W. Martin, Paul A. Kristiansen, Inger Marie Saga, Mamoudou Harouna Djingarey, Abdoul Salam Ouedraogo, Jennifer Dolan Thomas, Fabien Diomandé, Lassana Sangaré, Flavien Aké, Rasmata Ouédraogo, Sylvestre R. M. Tiendrebéogo, Thomas A. Clark, Denis Kandolo, Nancy E. Messonnier, Lara K. Misegades, F. Marc LaForce, Musa Hassan-King, Dominique A. Caugant, Idrissa Sanou
Publikováno v:
Clinical Infectious Diseases. 56:354-363
Background The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of 1-29-year-olds in Burkina Faso in 2010. It is not known whether MenAfriVac has an impact on NmA carri
Autor:
Marc LaForce, Lassana Sangaré, Jennifer Dolan Thomas, Pascal Kaboré, Rasmata Ouédraogo, Denis Kandolo, Paul A. Kristiansen, Mamoudou Harouna Djingarey, Marie-Pierre Préziosi, Abdoul-Salam Ouédraogo, Thomas A. Clark, Nancy E. Messonnier, Charles D. Ouédraogo, Cynthia Hatcher, Musa Hassan-King, Stanley C. Wei, Fabien Diomandé, Dominique A. Caugant, Idrissa Sanou, Ki Ba Absatou
Publikováno v:
Clinical and Vaccine Immunology. 18:435-443
The serogroup A meningococcal conjugate vaccine MenAfriVac has the potential to confer herd immunity by reducing carriage prevalence of epidemic strains. To better understand this phenomenon, we initiated a meningococcal carriage study to determine t
Autor:
Clement Lingani, Mamoudou Harouna Djingarey, Denis Kandolo, Ryan T. Novak, William Perea, Rodrigue Barry, Fabien Diomandé, Carol Tevi-Benissan, Florence Shirehwa, Marie-Pierre Preziosi, F. Marc LaForce
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background. A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically for the African “meningitis belt” and was prequalified by the World Health Organization (WHO) in June 2010. The vaccine was first used widely in Burkina Fas
Autor:
Kadidja Gamougam, Nehemie Mbakuliyemo, Denis Kandolo, Nancy E. Messonnier, James M. Stuart, F. Marc LaForce, Jean-Marc Collard, Paul A. Kristiansen, Ryan T. Novak, Doumagoum M. Daugla, William Perea, Brian Greenwood, Fabien Diomandé, Carol Tevi-Benissan, Mamoudou Harouna Djingarey, Marie-Pierre Preziosi, O. Walker, Thomas A. Clark, Dominique A. Caugant, Leonard W. Mayer
Publikováno v:
Clinical Infectious Diseases
Clinical Infectious Diseases, Oxford University Press (OUP), 2015, 61 (suppl_5), pp.S467-S472. ⟨10.1093/cid/civ499⟩
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases, Oxford University Press (OUP), 2015, 61 (suppl_5), pp.S467-S472. ⟨10.1093/cid/civ499⟩
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
International audience; Background. During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010–2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0f832aac82940364ba93875da5c003
https://researchonline.lshtm.ac.uk/id/eprint/2551457/1/civ499.PMC4639484.pdf
https://researchonline.lshtm.ac.uk/id/eprint/2551457/1/civ499.PMC4639484.pdf
Autor:
Paul A, Kristiansen, Absatou Ky, Ba, Abdoul-Salam, Ouédraogo, Idrissa, Sanou, Rasmata, Ouédraogo, Lassana, Sangaré, Fabien, Diomandé, Denis, Kandolo, Inger Marie, Saga, Lara, Misegades, Thomas A, Clark, Marie-Pierre, Préziosi, Dominique A, Caugant
Publikováno v:
BMC Infectious Diseases
Background The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, is currently being introduced throughout the African meningitis belt. In repeated multicentre cross-sectional studies in Burkina Faso we demonstrated a sig
Autor:
Desire Toboe, Clement Lingani, Stéphane Hugonnet, Nancy E. Messonier, Richard Mihigo, Denis Kandolo, Leonard W. Mayer, Patrick L.F. Zuber, William Perea, Mete Bonkoungou, F. Marc LaForce, Teresa Aguado, Nora Dellepiane de Rey Tolve, Carole Tevi-Benissan, Marie-Pierre Préziosi, Rodrigue Barry, Rene Sebgo, Mamoudou Harouna Djingarey, Fabien Diomandé, Dominique A. Caugant, Deo Nshimirimana, Monique Berlier, Thomas A. Clark, Sylvestre R. M. Tiendrebéogo, Ryan T. Novak, Paul A. Kristiansen
Publikováno v:
Vaccine. 30
A new Group A meningococcal (Men A) conjugate vaccine, MenAfriVac™, was prequalified by the World Health Organization (WHO) in June 2010. Because Burkina Faso has repeatedly suffered meningitis epidemics due to Group A Neisseria meningitidis specia